Inavolisib: a new treatment strategy for endocrine-resistant PIK3CA-associated luminal HER2-negative breast cancer

E. V. Lubennikova; E. V. Artamonova

Medical alphabet
Medicinskij alfavit

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

User

eng | рус

Medical alphabet

Advanced search

Archives

Download this PDF file

Fullscreen

For citations:

Lubennikova E.V., Artamonova E.V. Inavolisib: a new treatment strategy for endocrine-resistant PIK3CA-associated luminal HER2-negative breast cancer. Medical alphabet. 2026;(8):44-48. (In Russ.) https://doi.org/10.33667/2078-5631-2026-8-44-48

Views PDF (Rus): 60

JATS XML

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)

* not an advertisement

Indexing Databases

* not an advertisement

Popular articles

Editor-in-Chief

Petrikov Sergey S.

Article Tools

Finding References

Email this article (Login required)

Email the author (Login required)

About the Authors

E. V. Lubennikova
N. N. Blokhin National Medical Investigation Centre of Oncology
Russian Federation

Lubennikova Elena V., PhD Med Sci, senior researcher at Dept of Antitumor Drug Therapy No.1 Dept of Drug Treatment

Moscow

E. V. Artamonova
N. N. Blokhin National Medical Investigation Centre of Oncology; N. I. Pirogov Russian National Research Medical University (Pirogov University); M. F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation

Artamonova Elena V., Dr Med Sci (habil.), head of Dept of Antitumor Drug Therapy No.1 Dept of Drug Treatment; professor at Dept of Oncology and Radiation Therapy; head of Dept of Oncology and Thoracic Surgery

Moscow

Notifications

Username
Password
	Remember me
Not a user? Register with this site Forgot your password?

User

Medical alphabet

For citations:

Cookies policy